Goldman Sachs
ALXN

Goldman Sachs’s Alexion Pharmaceuticals ALXN Stock Holding History

Goldman Sachs’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-62,200
Closed -$11.4M – 6758
2021
Q2 		$11.4M Sell
62,200
-21,900
-26% -$3.76M ﹤0.01% 2562
2021
Q1 		$12.9M Sell
84,100
-100,800
-55% -$15.6M ﹤0.01% 2332
2020
Q4 		$28.9M Buy
184,900
+90,200
+95% +$11.6M 0.01% 1553
2020
Q3 		$10.8M Sell
94,700
-10,300
-10% -$1.11M ﹤0.01% 2252
2020
Q2 		$11.8M Buy
105,000
+58,300
+125% +$6.19M ﹤0.01% 2139
2020
Q1 		$4.19M Buy
46,700
+21,800
+88% +$2.14M ﹤0.01% 2778
2019
Q4 		$2.69M Hold
24,900
– – ﹤0.01% 3441
2019
Q3 		$2.44M Sell
24,900
-500
-2% -$56.4K ﹤0.01% 3408
2019
Q2 		$3.33M Buy
25,400
+5,000
+25% +$644K ﹤0.01% 3162
2019
Q1 		$2.76M Buy
20,400
+13,100
+179% +$1.63M ﹤0.01% 3395
2018
Q4 		$711K Hold
7,300
– – ﹤0.01% 4169
2018
Q3 		$1.01M Hold
7,300
– – ﹤0.01% 4051
2018
Q2 		$906K Sell
7,300
-5,200
-42% -$608K ﹤0.01% 4139
2018
Q1 		$1.39M Sell
12,500
-38,900
-76% -$4.65M ﹤0.01% 3835
2017
Q4 		$6.15M Sell
51,400
-91,400
-64% -$11.1M ﹤0.01% 2833
2017
Q3 		$20M Buy
142,800
+43,300
+44% +$5.88M ﹤0.01% 1985
2017
Q2 		$12.1M Sell
99,500
-157,200
-61% -$18.3M ﹤0.01% 2355
2017
Q1 		$31.1M Buy
256,700
+169,400
+194% +$21.8M 0.01% 1571
2016
Q4 		$10.7M Sell
87,300
-2,400
-3% -$294K ﹤0.01% 2424
2016
Q3 		$11M Sell
89,700
-23,700
-21% -$3.05M ﹤0.01% 2373
2016
Q2 		$13.2M Buy
113,400
+26,600
+31% +$3.77M ﹤0.01% 2103
2016
Q1 		$12.1M Buy
86,800
+20,700
+31% +$3.04M ﹤0.01% 2085
2015
Q4 		$12.6M Sell
66,100
-41,600
-39% -$7.27M ﹤0.01% 2074
2015
Q3 		$16.8M Buy
107,700
+61,000
+131% +$11.1M 0.01% 1841
2015
Q2 		$8.44M Buy
46,700
+15,600
+50% +$2.69M ﹤0.01% 2482
2015
Q1 		$5.39M Sell
31,100
-26,200
-46% -$4.74M ﹤0.01% 2814
2014
Q4 		$10.6M Buy
57,300
+15,700
+38% +$2.91M ﹤0.01% 2297
2014
Q3 		$6.9M Sell
41,600
-137,800
-77% -$22.6M ﹤0.01% 2705
2014
Q2 		$28M Sell
179,400
-34,700
-16% -$5.48M 0.01% 1532
2014
Q1 		$32.6M Buy
214,100
+171,300
+400% +$27.2M 0.01% 1370
2013
Q4 		$5.69M Sell
42,800
-6,500
-13% -$780K ﹤0.01% 2944
2013
Q3 		$5.73M Sell
49,300
-7,600
-13% -$834K ﹤0.01% 2795
2013
Q2 		$5.25M Buy
+56,900
New +$5.48M ﹤0.01% 2689

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Goldman Sachs's ALXN Position: Q3 2021 in Review

Goldman Sachs sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 781,412 shares — an estimated $144M sold.

Goldman Sachs first reported a position in ALXN in Q2 2013 and held it in 33 quarters. The position peaked at $584M in Q2 2017. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Goldman Sachs reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Goldman Sachs sold 781,412 Alexion Pharmaceuticals shares in Q3 2021, an estimated $144M.
  • Goldman Sachs first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 33 quarters.
  • Goldman Sachs's Alexion Pharmaceuticals position peaked at $584M in Q2 2017.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Goldman Sachs's 13F filing for Q3 2021, filed 10 Nov 2021.